Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034018 | 0.83 | CHEK1 (0.54) | CHEK1CDK5CDK5R1KDM4EATR | |
| SCHEMBL2031369 | 0.83 | CHEK1 (0.55) | CHEK1CDK5CDK5R1RPS6KA3SRPK1 | |
| SCHEMBL2037865 | 0.83 | CHEK1 (0.62) | CHEK1CDK5CDK5R1RPS6KA3SRPK1 | |
| SCHEMBL2034536 | 0.82 | CHEK1 (0.64) | CHEK1CDK5CDK5R1KDM4ERPS6KA3 | |
| SCHEMBL5165492 | 0.79 | CHEK1 (0.59) | CHEK1CDK5CDK5R1KDM4ESMN1; SMN2 | |
| SCHEMBL2036348 | 0.77 | CHEK1 (0.51) | CHEK1CDK5CDK5R1KDM4ERPS6KA3 | |
| SCHEMBL16416829 | 0.76 | CHEK1 (0.50) | CHEK1KDM4EATRRPS6KA3SRPK1 | |
| SCHEMBL14517910 | 0.76 | MEN1 (0.48) | CHEK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL2034311 | 0.75 | TSHR (0.58) | CHEK1SMN1; SMN2 | |
| SCHEMBL2036333 | 0.74 | KDM4E (0.51) | CHEK1CDK5CDK5R1KDM4ECHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379510-B1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS | ICOS CORP (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | CHEK1 1/4885CDK5 174/4885CDK5R1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.